Clinical trial · Observational
Sarcoidosis Immunotsuppressive Therapy and Lymphoma Development
Impact of Immunosuppressive Therapy of Sarcoidosis on Lymphoma Development
NCT07343401CI-TRIAL-00100987completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Impact of Immunosuppressive Therapy for Sarcoidosis on Lymphoma Development
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoidosis Lung | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| lymph node biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Inclusion criteria include adult patients (≥16 years) with histologically confirmed sarcoidosis, rec
- description
- This is a prospective observational cohort study to be conducted in the Chest Diseases Department, Alexandria Main University Hospital. A total of 40 adult patients (≥16 years) with biopsy-proven sarcoidosis will be consecutively recruited between December 2024 and December 2025. All patients will be either newly starting or continuing immunosuppressive therapy for sarcoidosis.
- interventionNames
- Procedure: lymph node biopsy
Primary outcomes (2)
- measure
- The primary outcome will be incident, biopsy-proven lymphoma during the 12-month follow-up.
- timeFrame
- 12 MONTHS
- description
- LYMPH NODE BIOPSY EITHER EXCISIONAL OR BRONCHOSCOPIC
- measure
- lymphoma development
- timeFrame
- 12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Inclusion criteria include adult patients (≥18 years) with histologically confirmed sarcoidosis, receiving or planned to receive immunosuppressive therapy Exclusion Criteria:Patients with a prior history of lymphoma or other active malignancy, HIV infection, or other primary immunodeficiency will be excluded. \-
References
Publications (0)
Data not yet available
No reference posted for this study.